Cargando…

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow (BM). MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morandi, Fabio, Horenstein, Alberto L., Costa, Federica, Giuliani, Nicola, Pistoia, Vito, Malavasi, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279879/ https://www.ncbi.nlm.nih.gov/pubmed/30546360 http://dx.doi.org/10.3389/fimmu.2018.02722

Ejemplares similares

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
por: Horenstein, Alberto L., et al.
Publicado: (2019)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

The Circular Life of Human CD38: From Basic Science to Clinics and Back
por: Horenstein, Alberto L., et al.
Publicado: (2020)

The Key Role of NAD(+) in Anti-Tumor Immune Response: An Update
por: Morandi, Fabio, et al.
Publicado: (2021)

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation
por: Morandi, Fabio, et al.
Publicado: (2015)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
por: Horenstein, Alberto L., et al.
Publicado: (2015)

CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance
por: Seckinger, Anja, et al.
Publicado: (2018)

Interactions between HLA-G and HLA-E in Physiological and Pathological Conditions
por: Morandi, Fabio, et al.
Publicado: (2014)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFNγ Cytokines and Proliferation
por: Fedele, Giorgio, et al.
Publicado: (2013)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
por: Horenstein, Alberto L, et al.
Publicado: (2013)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches
por: Bottino, Cristina, et al.
Publicado: (2014)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells
por: Morandi, Fabio, et al.
Publicado: (2019)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
por: Costa, Federica, et al.
Publicado: (2019)

CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy
por: Pape, Luca Julius, et al.
Publicado: (2022)

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma
por: Morandi, Fabio, et al.
Publicado: (2018)

Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
por: Morandi, Fabio, et al.
Publicado: (2021)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia
por: Pezzolo, Annalisa, et al.
Publicado: (2014)

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes
por: Deaglio, Silvia, et al.
Publicado: (2006)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)

Editorial: Advances in Immunotherapeutic Approaches to Tuberculosis
por: Estrada García, Iris, et al.
Publicado: (2021)

Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma
por: Lam, Jian Hang, et al.
Publicado: (2019)

Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma
por: Meyers, Daniel E., et al.
Publicado: (2017)

IL-27 Driven Upregulation of Surface HLA-E Expression on Monocytes Inhibits IFN-γ Release by Autologous NK Cells
por: Morandi, Fabio, et al.
Publicado: (2014)

Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis
por: Agarbati, S., et al.
Publicado: (2022)

Oncolytic Virotherapy and Microenvironment in Multiple Myeloma
por: Marchica, Valentina, et al.
Publicado: (2021)

Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma
por: Li, Wenting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kngcvkbi198ervk1pgg55qju5j